Kornimate/medical-research-clean huggingface dataset:
plasma and intracellular concentrations of raltegravir and etravirine administered once daily

Conditions: HIV-1 Infection; HIV Infections

Summary: hypothesis: the intracellular concentrations of raltegravir (ral) and etravirine (etv) administrated as 800 and 400 mg once a day, respectively, are similar to those obtained with the standard doses of 400 and 200 mg/12h, respectively. objective: to analyze the plasma and intracellular concentrations of ral and etv administrated as 800 and 400 mg once daily respectively compared with standard doses of 400 and 200 mg/12h, respectively, and if they support its once daily administration.

objective: to analyze the plasma and intracellular concentrations of ral and etv administrated as 800 and 400 mg once daily respectively compared with standard doses of 400 and 200 mg/12h, respectively, and if they support its once daily administration. method: phase iv, prospective, open labelled clinical trial with a planned duration of 24 weeks in which 16 patients from hospitales universitarios virgen del rocío will be enrolled. a 12 hours pharmacokinetic profile (immediately before and after 1, 2, 3, 4, 6, 8, 10 and 12 h) will be obtained after a supervised drug intake while taking ral or etv bid. afterwards,the patients will take ral or etv once a day for 7 - 10 days. subsequently, a new pharmacokinetic profile (predose and after 1, 2, 3, 4, 6, 8, 10, 12, 16, 20 and 24 h after a supervised drug intake) will be obtained.

Eligibility criteria:
inclusion criteria: * adult hiv-1-infected patients taking raltegravir- or etravirine-based antiretroviral regimens exclusion criteria: * pregnancy * concomitant use of drugs that have potential interactions with raltegravir or etravirine pharmacokinetics * cirrhosis with clinical or analytic data of liver failure. * clinical history suggesting malabsorption or presence of diarrhea (\> 3 stools / day) that could interfere with the absorption of study drugs.

Keywords: raltegravir etravirine pharmacokinetics intracellular
effectiveness of kos-862 in the treatment of lung cancer

Conditions: Lung Cancer

Summary: the purpose of this study is to determine whether a potential drug known as kos-862 or "epothilone d" has an effect as a 2nd line treatment in non-small cell lung cancer (nsclc) for patients having failed one prior platinum-containing chemotherapy regimen.

to determine the antitumor activity, based on the confirmed objective response rate, of kos-862, administered intravenously weekly for 3 weeks every 4 weeks, in patients with non-small cell lung cancer (nsclc) whose disease has progressed following initial chemotherapy for advanced or metastatic disease.

Eligibility criteria:
inclusion criteria: * at least 18 years of age * measurable disease * one previous treatment of a platinum based drug such as cisplatin or carboplatin * at least 3 weeks since last surgery/radiation/chemotherapy exclusion criteria: * brain metastases * changes in the rhythm of your heart that are considered significant as determined by an ecg tracing
quantitative eeg assessment of cue-induced changes in brain activity in alcohol use disorders

Conditions: Alcohol Craving

Summary: exposure to alcohol related cues, such as the sight of alcoholic drinks, may induce craving for alcohol in drinkers. in this study, the effects of exposure to (1) the pictures of alcoholic drinks and (2) the imagining of a scene related to drinking on activity in the frontal region of the brain in heavy social drinkers will be determined. this study is being conducted to develop the methods needed to allow for the detection of cue-induced changes in drinkers using the eeg. the objective of this pilot study is to establish procedures for detecting alcohol-related cue-elicited changes in eeg activity in heavy drinkers.


Eligibility criteria:
inclusion criteria: 1. male or female, aged 21 to 70. 2. history of heavy drinking: defined as at least 8 occasions in the past month that individual had at least 5 drinks (males) or 4 drinks (females) in one sitting. 3. the subject must currently not be in treatment for any alcohol use disorder 4. subject must be able to comprehend and perform study related information and tasks in english and have a willingness to complete study procedures. 5. subject must be able to provide written informed consent, at time of consent bac has to be 0.00%. 6. the subject must have the ability to read/speak english exclusion criteria: 1. severe impairment of sight, smell, or hearing that would result in a significant alteration in the response to alcohol related cues. 2. currently on a medication used to treat alcoholism or is known to alter eeg activity or responsiveness to cue presentation including acamprosate, anticonvulsants, anticholinergics, antipsychotics, benzodiazepine receptor agonists, beta adrenergic receptor antagonists, and naltrexone. 3. history of any neurological or psychiatric disorder that would result in abnormal eeg activity such as severe brain trauma, seizure disorders, stroke or that would severly alter response to the cue presentation such as schizophrenia or any other psychotic or severe mood disorder. 4. ciwa-ar score of 8 or higher or any history indicating that the subject is at risk for experiencing severe alcohol withdrawal symptoms if her or his drinking is discontinued for any period of time. 5. the subject must not be pregnant. -

Keywords: eeg related visual and verbal cues
pilot study of virtual reality therapy for students with anxiety

Conditions: Anxiety

Summary: the purpose of this study is to assess changes in self-reported anxiety over the course of six virtual reality (vr) sessions and to assess changes in academic self-efficacy, as well as examine the feasibility and acceptability of a relatively short and time intensive vr intervention (i.e.,six sessions over the course of three weeks) for reducing anxiety symptoms in college students.


Eligibility criteria:
inclusion criteria: * enrolled in the university of texas health science center school of public health san antonio regional campus * competent in english * total score of at least 3 on the generalized anxiety disorder (gad-2) exclusion criteria: * currently receiving psychological treatment for anxiety symptoms, or has received treatment in the last year. * report photosensitive epilepsy. * report stereoscopic vision or balance problems

Keywords: virtual reality college students
telephone cognitive behavioral therapy for veterans undergoing surgery

Conditions: Persistent Post-surgical Pain; Veterans

Summary: the study team propose to investigate the feasibility and pilot a telephone cognitive behavioral therapy intervention for those identified to be at risk for chronic pain following surgery.


Eligibility criteria:
inclusion criteria: 1) \>18 years of age, 2) scheduled for hernia repair, breast surgery, amputation, thoracotomy, cholecystectomy, cardiac surgery, splenectomy, orthopedic, urological or vascular surgery, 3) rural dwelling exclusion criteria: 1) language or cognitive barriers preventing completion of questionnaires, 2) severe psychiatric disorder: bipolar or psychotic disorder, 3) significant surgical complications.
the clinical difference between the nonfatal patients and the fatal patients with severe covid-19

Conditions: Coronavirus Disease 2019; Character of the Severe Patients

Summary: to investigate the difference of the difference between the nonfatal coronavirus disease 2019 (covid-19) patients and the fatal patients .the cross sectional study was undertaken to compare the clinical information (laboratory and radiologic characteristics)of nonfatal participants and fatal cases. the investigators wish figure out the clinical character of the fatal participants. the result may help the physician to find the fatal patients with covid-19 more easily. the fatal patients with covid-19 could be treated early.


Eligibility criteria:
inclusion criteria: * the patients with coronavirus disease 2019 * positive result on real-time reverse-transcriptase-polymerase-chain-reaction * positive result on chest computed tomography exclusion criteria: * no
encouraging a plant based diet in an underserved urban population

Conditions: Food Neophobia; Food Preferences; Dietary Habits

Summary: the investigator's goal is to promote a plant-based diet amongst the underserved urban population of louisville with the help of educational aids and the provision of affordable resources.

primary care clinic patients who screen positive for food insecurity between 2021-2023 will be eligible for this study (\~200 patients). patients will be recruited by one of four means: during standard clinic visits, or via phone, electronic medical record message, or mail. registry of patients will be de-identified and list of identifiers will be stored separately from the data set. data will be stored on password protected computers only available to select research staff. investigators will utilize a preamble in lieu of informed consent. the primary outcome will be to measure the readiness of patients to adhere to a plant-based diet. investigators will assess readiness using food neophobia inventory and will perform a brief diet inventory at simultaneous timepoints. education surrounding benefits and easy ways to increase plant-based eating will be distributed to all participating patients. enrollment in a local income-based subsidized community supported agriculture share (weekly farm produce box during growing season) will be offered to all patients. patients can opt into this service, and we will track which patients enroll. before, during, and after the community sponsored agriculture produce time period, food neophobia and diet inventory will be reassessed. adherence to plant-based eating between the patients who received access to subsidized food and education versus those who received education alone will be evaluated. qualitative open-ended feedback will be obtained at all time points. the secondary outcomes are to measure weight loss, reduction in blood pressure, and improvement in hemoglobin a1c and lipid profile wherever applicable. statistical significance is not attempting to be reached, but rather the associations between food neophobia and ability to change diet will be evaluated, as well as other qualitative open-ended feedback.

Eligibility criteria:
inclusion criteria: * patients age 18 and older screening as food insecure since 2021 * patients willing to complete survey data exclusion criteria: * n/a

Keywords: food neophobia, plant-based diet
genetic epidemiology risk assessment program or usual care in colorectal cancer screening for healthy participants

Conditions: Colorectal Cancer; Healthy, no Evidence of Disease

Summary: rationale: the genetic epidemiology and risk assessment program may be more effective than usual care in increasing the number of healthy participants who regularly receive screening for colorectal cancer. purpose: this randomized clinical trial is studying the genetic epidemiology and risk assessment program to see how well it works compared with usual care to increase colorectal cancer screening in healthy participants.

objectives: * compare genetic epidemiology and risk assessment (gera) feedback vs usual care (uc) in terms of colorectal cancer (crc) screening utilization by healthy participants. * determine the impact of gera feedback and uc on psychological distress in these participants. * compare gera feedback vs uc in terms of intention to have crc screening, perceived crc risk, crc knowledge, salience and coherence of crc screening, and support for crc screening in these participants. * identify factors that moderate the impact of gera feedback on crc screening utilization. outline: this is a randomized study. participants are randomized to 1 of 2 screening arms. * arm i: participants receive standard primary care. * arm ii: participants receive standard primary care followed by the genetic epidemiology and risk assessment (gera) intervention. participants also participate in a discussion session regarding the gera including the rationale behind methylenetetrahydrofolate reductase mutation detection and folate assessment and its relationship to colorectal cancer risk. all participants undergo a fecal occult blood test 3 weeks after the screening office visit. projected accrual: a total of 1,950 participants will be accrued for this study.

Eligibility criteria:
disease characteristics: * healthy participants meeting the following criteria: * no personal history of colorectal polyps or cancer or inflammatory bowel disease * no family history of familial adenomatous polyposis, hereditary nonpolyposis colorectal cancer (crc), or crc in more than 1 first-degree relative * nonadherent with standard crc screening recommendations at the time of their index office visit patient characteristics: * able to communicate with ease in english prior concurrent therapy: * more than 6 weeks since prior antibiotics or antifolate medications (e.g., sulfasalazine, methotrexate)

Keywords: colon cancer rectal cancer healthy, no evidence of disease
effect of glucose control on the response to aspirin in type 2 diabetic patients

Conditions: Diabetes Mellitus, Type II

Summary: the efficacy of low dose aspirin appears to be substantially lower in diabetic patients, compared to patients without diabetes. we will perform an observational study where we follow up patients with uncontrolled type 2 diabetes mellitus and low response to aspirin (aspirin resistance), during a period of 6 months in the diabetic clinic. our hypothesis is that glucose control will improve the response to aspirin in those patients.


Eligibility criteria:
inclusion criteria 1. type 2 dm. 2. patients that take aspirin. 3. antecubital forearm veins allowing technically good sampling for platelet studies. 4. reduced laboratory response to aspirin. 5. hba1c \> 8 % 6. the physician decides that there is an indication for glucose control. exclusion criteria: 1. acute ischemic stroke, acute coronary syndrome, (myocardial infarction or unstable angina pectoris), or revascularization by pci or by-pass surgery within the last 6 months. 2. acute kidney disease or chronic kidney disease with creatinine clearance \<30. 3. acute liver disease or chronic liver disease with severe liver impairment. 4. need for treatment with anticoagulants, clopidogrel, nsaid's, or thiazolidinediones. 5. thrombocytopenia (platelet count \<150 x 109/l)

Keywords: diabetes mellitus type ii aspirin resistance
a study evaluates the safety, pharmacokinetics, immunogenicity and efficacy of qls31903 in advanced solid tumor patients

Conditions: Advanced Solid Tumors

Summary: the purpose of the study is to evaluate safety, pharmacokinetics,immunogenicity and efficacy of qls31903 alone in the treatment of advanced cancer.


Eligibility criteria:
key inclusion criteria: * 18 years or older, 40kg or heavier * histologically or cytologically confirmed diagnosis of advanced solid tumor （for phase 1b, patients must have solid tumor with gpc3+ ) * standard treatment failed or standard treatment intolerant, no standard treatment * adequate hepatic, hematologic, and renal function key exclusion criteria: * anti-tumor treatment within 4 weeks prior to the first qls31903 administration,except a few specific conditions * other clinical trial within 4 weeks prior to the first qls31903 administration * receipt of a live or live attenuated vaccine within 30 days prior to the first qls31903 administration * prior treatment targeted on gpc3 * hbsag/hbcab positive and hbv-dna\>10,000 copy/ml;hcv-ab positive and hcv-rna\>1,000 copy/ml * cns metastasis (except asymptomatic brain metastases or symptomatic brain metastases after treatment stable for more than 4 weeks) and/or carcinomatous meningitis or leptomeningeal disease
evaluation of a rwanda hospital feeding program on nutrition, recovery, costs of care and health related quality of life

Conditions: Nutrition

Summary: the purpose of this interventional study was to evaluate outcomes for solid'africa's gemura feeding program in four selected public hospitals comparing results between patients receiving and patients not receiving the feeding program. the study measured the effects of the program on patients nutritional status, recovery during hospitalization, patient health related-quality of life, patient satisfaction, and patient costs of care. participants were asked: (1) to eat meals provided three times a day if they were in the intervention group; (2) to participate in an intake and discharge survey; and (3) to participate in a daily food intake survey.

a multi-center, quasi-experimental study using difference-in-differences controlled comparison to test the outcomes of solid'africa's gemura feeding intervention in four selected public hospitals (two in intervention group and other two in control group) from urban and peri-urban areas targeting socioeconomically vulnerable inpatients. this study has a primary outcome which is nutritional status as measured by body mass index (bmi), and secondary outcomes which include recovery during hospitalization, patient health-related quality of life (hrqol), patient satisfaction, and patient costs of care.

Eligibility criteria:
inclusion criteria: * hospital inpatients * vulnerable socioeconomic status according to social worker assessment * most inpatient categories * voluntary, self-feeding ability * able to stand on scale, with help if needed exclusion criteria: * hospital outpatients * patients not determined socioeconomically vulnerable by social worker * pregnant women hospitalized for delivery * patients undergoing special treatment for malnutrition * patients receiving enteral or parenteral nutrition treatment * patients receiving any kind of artificial feeding support * patients unable to stand on scale to measure weight

Keywords: nutrition hospitals, public malnutrition sub-saharan africa food intake
refinement and adaption of reinforcement learning to personalize behavioral messaging for healthy habits

Conditions: Diabetes Mellitus, Type 2; Medication Adherence

Summary: reinforcement learning is an advanced analytic method that discovers each individual's pattern of responsiveness by observing their actions and then implements a personalized strategy to optimize individuals' behaviors using trial and error. the goal of the proposed research is to refine, adapt and perform efficacy testing of a novel reinforcement learning-based text messaging intervention to support medication adherence for patients with type 2 diabetes within a community health center setting. this study will be a parallel randomized pragmatic trial comparing medication adherence and clinical outcomes for adults in a community setting aged 18-84 with type 2 diabetes who are prescribed 1-3 daily oral medications for this disease. participants will be randomized to one of two arms for the duration of the study period: (1) a reinforcement learning intervention arm with up to daily, tailored text messages based on time-varying treatment-response patterns; or (2) a control arm with up to daily, un-tailored text messages. outcomes of interest will be medication adherence, as measured by electronic pill bottles, and hba1c levels over 6 months.

the goal of the proposed research is to refine, adapt and perform efficacy testing of a novel reinforcement learning-based text messaging intervention to support medication adherence for patients with type 2 diabetes within a community setting. type 2 diabetes is an optimal condition in which to refine this program, as it is one of the most prevalent chronic conditions in the us adult population and requires most patients to be on daily or twice daily doses of medications. this study will be a parallel randomized pragmatic trial comparing medication adherence and clinical outcomes for adults in a community setting aged 18-84 with type 2 diabetes who are prescribed 1-3 daily oral medications for this disease. participants will be randomized to one of two arms for the duration of the study period: (1) a reinforcement learning intervention arm with up to daily, tailored text messages based on time-varying treatment-response patterns; or (2) a control arm with up to daily, un-tailored text messages. outcomes of interest will be medication adherence, as measured by electronic pill bottles, and hba1c levels over 6 months.

Eligibility criteria:
inclusion criteria: * diagnosis of type 2 diabetes mellitus (t2dm) * prescribed between 1-3 daily oral medications for diabetes * most recent hba1c level of 7% or greater * suboptimal adherence, defined by proportion of days covered (pdc) \< 0.90 based on chart review * must have a smartphone for which they are the sole user * must have a basic working knowledge of english or spanish exclusion criteria: * currently using a pillbox and/or not willing to use electronic pill bottles for 6 months * receive help at home on a daily basis with taking medications
a study to evaluate the safety and efficacy of azithromycin in individual patients with serious nontuberculous mycobacterial disease who are failing or intolerant of other available therapy

Conditions: Mycobacterium Avium-Intracellulare Infection; HIV Infections; Tuberculosis, Mycobacterium Infection

Summary: to evaluate the efficacy and safety of azithromycin given chronically for the treatment of serious nontuberculous mycobacterial infection in patients failing or intolerant of other available therapy.


Eligibility criteria:
inclusion criteria concurrent medication: allowed: * other antimicrobial drugs as long as documented on case report form. patients must have: * serious nontuberculous mycobacterial infection. * approval of eligibility from pfizer clinical monitor. patients below the legal age of consent must have consent of parent or guardian. note: * pregnant women, women of childbearing potential, and children will not be specifically excluded from participation. however, patients and physicians should be aware that the safety of azithromycin during pregnancy and in long-term use in children and adults has not been established. the risks and benefits of azithromycin use in these patients will be considered in consultation with the physician and the pfizer clinical monitor. exclusion criteria co-existing condition: patients with the following symptoms or conditions are excluded: * disseminated mycobacterium avium complex (mac) who are eligible for treatment with azithromycin under protocol 066-162. * known hypersensitivity or intolerance to macrolide antibiotics. patients with the following prior conditions are excluded: history of hypersensitivity or intolerance to azithromycin.

Keywords: mycobacterium avium-intracellulare infection acquired immunodeficiency syndrome azithromycin mycobacterium infections, atypical